bioAffinity Technologies, Inc. — Form 8-K
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
bioAffinity Technologies reported Q2 2026 CyPath Lung sales growth >200% year-over-year and 30% sequentially, with 155% increase in physician offices ordering the test versus Q2 2025. The company has now performed nearly 3,000 tests total since commercial launch, with expanding adoption across pulmonology practices, lung nodule clinics, academic centers, and VA facilities. No specific revenue dollar amounts, test pricing, or customer count are disclosed.
Why this rating
Strong operational momentum in early-stage biotech with $22.6M market cap; >200% YoY growth in commercial product is material, but no revenue figures disclosed to assess absolute magnitude relative to company size.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.